Applications Vaccixcell

Cervical Cancer Vaccine

Cervical cancer is a form of cancer that originates from the cervix. It is usually caused by Human Papillomavirus (HPV). Vaccines that protect from HPV are widely available in the market however it only protects against several of the virus strains, not all of them. Because of this, it is still possible for someone to have taken the prophylactic vaccine and still be diagnosed with cervical cancer.

Cervical cancer also has quite a mortality rate, with an estimate of more than 30% of patients die within the first five years from diagnosis. It is one of the most common type of cancer and the 4th most common cancer related death in women.


Treatments for cervical cancer includes surgery, chemotherapy and radiotherapy. The earlier the cancer is detected and managed, the bigger the chance of survival or at least prolonging the patient's life. None of these treatment methods however are guaranteed to cure the said cancer. In addition, most of these treatments has severe side effects.

In light of this, there are new developments in the field of therapeutic vaccine of cervical cancer which might be prove to be more effective with less side effects.

One of these therapeutic vaccines is called VGX-3100. It is a form of DNA vaccine that is now in Phase II testing for treatment of cervical cancer. The way the vaccine works is that is inserts DNA into the patient's cells such that it would produce antibodies and T-cells for the target cells. Such a treatment would not only be much safer, it would also have the potential of being a long term solution.


In the upstream bioprocessing required in creating DNA vaccines, VacciXcell's TideMotion bioreactor is the best choice available in the current market. Click here to learn more:


VGX-3100 - 10 promising therapeutic vaccines